Kymera Therapeutics (KYMR) Misses Q1 EPS by 5c

Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.71), $0.05 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $9.62 million versus the consensus estimate of $16.23 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
• Vail Resorts taps bankers for potential activist defense, Semafor reports